Cancer Treatment Reviews

Papers
(The TQCC of Cancer Treatment Reviews is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Editorial Board250
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives235
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty233
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in175
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review157
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis146
Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming126
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer111
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer94
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer86
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials84
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)83
Editorial Board82
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era81
Emerging antibody-based therapies for the treatment of acute myeloid leukemia77
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.75
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features70
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches67
Optimizing care in early phase cancer trials: The role of palliative care66
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis64
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?64
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment63
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis61
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma61
De-escalation strategies with targeted therapies in non-small cell lung cancer58
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications58
If it’s a target, it’s a pan-cancer target: Tissue is not the issue58
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC54
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials52
Editorial Board50
Uncertainties and controversies in axillary management of patients with breast cancer49
Editorial Board48
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation48
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy48
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes46
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck46
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations45
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment45
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?45
Corrigendum to “The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management”. [Cancer Treat. Rev. 139 (2025) 102998]44
Extracellular vesicles and the “six Rs” in radiotherapy44
Managing strategies of chemotherapy and radiotherapy-induced oral mucositis44
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?44
HER-2 directed therapies across gastrointestinal tract cancers – A new frontier43
Editorial Board42
Overview of BH3 mimetics in ovarian cancer42
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review42
The immunogram of inflammatory breast cancer42
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design41
Deciphering primary acinic cell carcinoma of the Breast: Insights from a comprehensive case series and Systematic review40
Circulating tumor DNA as prognostic marker in patients with metastatic colorectal cancer undergoing systemic therapy: A systematic review and meta-analysis40
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada39
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside38
The management of colorectal liver metastases amenable of surgical resection: How to shape treatment strategies according to clinical, radiological, pathological and molecular features38
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma37
Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities36
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma36
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers36
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)36
The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives36
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review35
Editorial Board35
Long-term surveillance recommendations for young adult cancer survivors35
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer35
Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies35
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review34
Agnostic drug development revisited34
Angiogenesis and thymic epithelial tumors: from preclinical insights to different therapeutic lines and combination strategies34
Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life32
Assessing lung function in women treated for breast cancer with radiotherapy. A comprehensive systematic review and meta-analysis32
Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer32
Bone complications of cancer treatment31
Malignant ascites: Current therapy options and treatment prospects31
Systematic review of the CUP trials characteristics and perspectives for next-generation studies31
Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review30
Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers30
Immunocytokines in cancer treatment: A systematic review30
Editorial Board30
Effectiveness of immune checkpoint inhibitor therapy in thyroid cancer: A systematic review28
Editorial Board28
Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review28
Acknowledgement to Reviewers 202128
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis27
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?27
Local control strategies for management of NSCLC with oligoprogressive disease27
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?27
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review27
Genomic distinctions in adolescent and young adult cancer: A comprehensive review27
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review26
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification26
Clinical development of WEE1 inhibitors in gynecological cancers: A systematic review26
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges25
Corrigendum to “T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis”. [Cancer Treat Rev. 139 (2025) 102991. doi: 10.1016/j.ctrv.2025.102991]25
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications25
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes25
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project24
Comparative efficacy and safety of pyrotinib plus trastuzumab versus trastuzumab plus pertuzumab and trastuzumab monotherapy in neoadjuvant treatment of HER2-positive breast cancer: A systematic revie24
Engineering strategies to optimise adoptive cell therapy in ovarian cancer24
Patient-reported outcome measure to implement routine assessment of cancer survivors’ unmet needs: An overview of reviews and COSMIN analysis24
Radiotherapy dose escalation using endorectal brachytherapy in elderly and frail patients with rectal cancer unsuitable for surgery: Lessons from studies in fit patients and future perspectives24
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis24
Review: Targeting EZH2 in neuroblastoma24
Strategies for improving detection of circulating tumor DNA using next generation sequencing23
Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis23
PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence23
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer23
Evolving immunotherapeutic solutions for triple-negative breast carcinoma23
Corrigendum to “SELNET clinical practice guidelines for soft tissue sarcoma and GIST” [Cancer Treat. Rev. 102 (2021) 102312]23
Pharmacotherapy for leptomeningeal disease in breast cancer23
Editorial Board22
Editorial Board22
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression22
SELNET clinical practice guidelines for soft tissue sarcoma and GIST22
Diagnostic utility of urinary cell-free DNA in non-urothelial cancer: a systematic review, meta-analysis, & network meta-analysis21
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis21
Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review21
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications21
Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review21
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies21
Addition of immune checkpoint inhibitors to chemotherapy versus chemotherapy alone in first-line metastatic triple-negative breast cancer: A systematic review and meta-analysis20
Clinical overview of trophoblast surface antigen 2 Antibody-Drug conjugates in Non–Small cell lung cancer20
Editorial Board20
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis20
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy20
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment20
Considerations regarding a network meta-analysis of targeted therapies for BRAF-mutant unresectable or metastatic melanoma20
Editorial Board20
Datopotamab deruxtecan: rational strategies, novel advancements, challenges, and future perspectives20
Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases20
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672]20
0.23367595672607